169 related articles for article (PubMed ID: 7589338)
1. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
4. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Enblad G; Hagberg H; Glimelius B
Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
7. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Nowrousian MR; Anders CH; Niederle N; Nagel-Hiemke M; Moritz T; Seeber S; Schmidt CG
Ann Oncol; 1991 Jan; 2 Suppl 1():25-30. PubMed ID: 1710486
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Mayer J; Korístek Z; Vásová I; Müllerová I; Král Z; Navrátil M; Klabusay M; Vorlícek J; Vodvárka P; Hejlová N; Penka M; Krahulcová E; Tomíska M; Adam Z; Hájek R
Cas Lek Cesk; 1998 Oct; 137(19):590-7. PubMed ID: 9818471
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
11. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
13. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
[TBL] [Abstract][Full Text] [Related]
17. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
[TBL] [Abstract][Full Text] [Related]
18. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
